Clinically visible progression indicators in age-related macular

degeneration are transdifferentiated retinal pigment epithelium

Dongfeng Cao PhD[1‡], Belinda Leong MD[2,4‡], Jeffrey D. Messinger DC [1], Deepayan

Kar MS [1], Thomas Ach MD[5], Lawrence A. Yannuzzi MD [2,3], K. Bailey Freund MD[2,3,6],

Christine A. Curcio PhD[1]*

[1]Department of Ophthalmology and Visual Sciences, University of Alabama at

Birmingham School of Medicine; Birmingham, AL, USA.

[2]Vitreous Retina Macula Consultants of New York; New York, NY, USA.

[3]LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital;

New York, NY, USA.

[4]Retina Associates; Sydney, NSW, Australia.

[5]Department of Ophthalmology, University Hospital Bonn; Bonn, Germany.

[6]Department of Ophthalmology, New York University, Grossman School of Medicine;

New York, NY, USA.

*Corresponding author. Email: christinecurcio@uabmc.edu

[‡]These authors contributed equally to this work.

Words: 9622 (main), **Figures:** 6; **Supplementary figures:**10; **Supplementary tables:**

7

One Sentence Summary

In age-related macular degeneration retinal pigment epithelial cells transdifferentiate and

migrate into the retina where they are clinically visible progression risk indicators.

Abstract

Age-related macular degeneration (AMD) is a common sight-threatening disease of

older adults and treatment options are needed. Abnormalities of retinal pigment

epithelium (RPE), supporting cells to photoreceptors and capillaries, are a hallmark.

Clinical optical coherence tomography (OCT) imaging reveals hyperreflective foci (HRF)

that confer risk for end-stage disease and are attributed to ectopic out-of-layer RPE.

Using longitudinal OCT imaging of AMD patients, we demonstrate that the trajectory of

one HRF form, RPE plume, parallels the retinal Henle fiber layer. Histology shows fully

pigmented cells approaching and contacting retinal capillaries with RPE organelles

dispersing along Müller glia columns. We used immunohistochemistry and a system of

morphologic phenotypes to assess RPE functional repertoire in AMD. RPE

corresponding to HRF loses immunoreactivity for retinoid processing proteins RPE65

and CRALBP, and gains immunoreactivity for immune cell markers CD68 and CD163.

Müller glia retain CRALBP immunoreactivity. Gain- and loss-of-function for RPE starts

with individual in-layer cells and extends to all abnormal phenotypes. Down-regulated

RPE retinoid handling may contribute to slowed rod vision while Müller glia sustain cone

vision. Ectopic RPE corresponding to HRF are emblematic of widespread

transdifferentiation, motivating treatments targeting AMD pathology earlier than the

initiation of atrophy. Data can propel new biomarkers and therapeutic strategies for

AMD.

Abbreviations: AMD, Age-related macular degeneration; BLamD, basal laminar

deposit; BrM, Bruch's membrane; Ch, choroid; ChC, choriocapillaris; cRORA,

complete RPE and outer retinal atrophy; d, drusen; ELM, external limiting

membrane; EZ, ellipsoid zone; fv scar, fibrovascular scar; GCL, Ganglion cell layer;

HFL, Henle fiber layer; ILM, internal limiting membrane; IPL, inner plexiform layer; INL,

inner nuclear layer; IS, inner segments of photoreceptors; iRORA, complete RPE and

outer retinal atrophy; IZ, interdigitation zone; nvAMD, neovascular AMD; ONL, outer

nuclear layer; OPL, outer plexiform layer; OS, outer segments of photoreceptors; R,

retina; Sc, sclera; SRS, subretinal space; x, detachment.

INTRODUCTION

Age-related macular degeneration (AMD) causes vision loss in older persons worldwide

(*1*). Neovascular complications are managed medically (*2*), whereas the underlying and

prevalent atrophic ("dry") disease is not yet treatable. AMD affects vertically integrated

cellular layers formed by light-sensing photoreceptors and support cells (retinal pigment

epithelium (RPE), choriocapillaris, Müller glia). Characteristic extracellular deposits

(drusen, subretinal drusenoid deposits) form between photoreceptors and their choroidal

and retinal blood supplies (*3*). RPE cells supporting photoreceptors and vessels are

central to, and impacted by, both atrophic and neovascular AMD.

AMD is increasingly understood via clinical imaging, particularly optical coherence

tomography (OCT). This technology provides depth-resolved views of retinal and

choroidal tissue layers (*4*) and is amenable to histologic validation (*5*). A progression

sequence for drusen-initiated atrophy is age-related deterioration in choriocapillaris and

Bruch's membrane (a vascular wall) preventing egress of wastes to the circulation,

growth of drusen with death or migration of overlying RPE, and reactive gliosis (*5*). To

the vision-initiating photoreceptors, AMD is a disease of the re-supply route for retinoids

(vitamin A derivatives) translocated from the circulation across the affected tissue layers

(*6*). Rod-mediated (dim light) vision is affected first, because rods depend on these

layers (*7*). Cone-mediated (bright light) vision, also sustained by Müller glia and retinal

vessels (*8*), persists into later disease. In this overall model, the RPE is a readout of

pathology in the less visible Bruch's membrane and choriocapillaris. RPE fate in AMD

can be uniquely monitored in vivo, because each cell has >1400 organelles (*9*) capable

of generating OCT signal, and OCT is widely used in the management of neovascular

AMD.

Longitudinal studies and post-hoc analysis of clinical trial imaging datasets

revealed OCT biomarkers for progression from intermediate AMD to geographic atrophy.

Tissue damage in atrophy is severe and possibly irreversible (*10*). Identifying trial

outcome measures earlier than expansion of atrophy, currently the only measure

accepted by the U.S. Food and Drug Administration, is the goal of an international

consensus group (*5, 11-13*). Of OCT biomarkers, hyperreflective foci (HRF) within the

neurosensory retina confer the largest risk for progression (*14-17*). HRF correspond to

ectopic RPE that detach from the layer and migrate anteriorly. A histologic survey of

RPE phenotypes (*18-20*), confirmed in clinically characterized eyes (*18, 21*), identified

two phenotypes corresponding to HRF, "sloughed" (among the photoreceptors) and

"intraretinal" (within the neurosensory retina). In a hypothetical progression sequence

(fig. S1), morphologically distinct cells deploy along separate pathways of cell fate,

including death, migration, and transdifferentiation to other cell types, without intervening

dedifferentiation and proliferation (*22*). Due to migration and death-in-place of RPE, the

layer disintegrates, scattering fully pigmented and nucleated cells ("dissociated") across

atrophic areas. Some cells appear to dive below the intact layer and migrate outside the

atrophic area ("subducted") (*19*).

To investigate whether one HRF form called "RPE plume" exhibits the behavior of

cells crossing the retina in parallel with the Henle fiber layer (HFL) (fig. S2), we herein

provide a clinical OCT timeline for this feature in patients with AMD. Applying

immunohistochemistry of human donor eyes to test whether HRF are transdifferentiated,

we show loss of retinoid processing and gain of immunologic function in all abnormal

RPE phenotypes. To complete a HRF lifecycle, we show RPE-derived debris in relation

to the cross-retinal course of Müller glia. Because RPE transdifferentiation is

widespread, a strategy of visualizing and targeting pathology earlier in AMD progression

than atrophy is warranted.

RESULTS

Clinical imaging

Four morphologies of RPE plume were defined (Fig 1). Curvilinear plumes (Fig. 1A)

appear as hyperreflective features of constant width, above the RPE layer with or

without drusen, and pointing towards the outer plexiform layer. Relative to curvilinear,

comma plumes (Fig. 1B) are similarly reflective, with a wider base at the RPE layer and

tapering anteriorly. Like curvilinear, thread plumes (Fig. 1C), previously seen in inherited

retinopathies (23), are of uniform width but are thinner. A vitelliform plume (Fig. 1D) is

thick at its base, typically an acquired vitelliform lesion (autofluorescent and yellow

subretinal extracellular material) (24), with an anterior taper that widens over time.

To observe plume lifecycles and intraretinal trajectories, 44 patients with non-

neovascular AMD (61 eyes, 29 females, 79.4 years (standard deviation 7.7 years)) with

at least one HRF and mean follow-up duration of 4.67 years (standard deviation 0.09

years) were enrolled (table S1). In 29 eyes of 21 patients (15 female), 129 plumes were

followed for locations and characteristics including presence of complete and incomplete

RPE and outer retinal atrophy (cRORA, iRORA) (5, 12). Plumes obliquely crossing

horizontally oriented OCT B-scans appeared as small reflective dots that were

connected by inspecting consecutive scans (fig. S3). Over time individual plumes

evolved considerably (Fig. 2), converting from one morphology to another (Fig. 2A to 2E)

or to discrete HRF (i.e., unconnected to the RPE layer) (Fig. 2A and 2F), disappearing

with (Fig. 2A, 2C and 2D) or persisting after (Fig. 2A, 2C and 2E) druse collapse to

atrophy, or even predating druse appearance (Fig. 2E).

Curvilinear and thread plumes were the most common morphologies at baseline

and the longest lasting over follow up (fig. S4A). Plume number and dynamism (i.e.,

appearance, disappearance, and conversions) could be striking (fig. S4B). Of 129

plumes at baseline (table S2), 73 (56.5%) converted to another plume morphology or

discrete HRF during follow-up, with 38 disappearing and 35 remaining; 56 (43.4%)

plumes retained the original morphology.

Most plumes (101/129, 78.2%) were geometrically congruent with the local

trajectory of the normal HFL (table S3), especially temporal to the fovea, with more non-

congruent plumes superior nasal to the fovea. Of 129 plumes, 73/129 (56.5%) were

associated with cRORA. Near cRORA, plumes were seen traveling in directions

unrelated or opposite to the normal HFL (fig. S5). Accordingly, at the final visit (table S4),

43/129 (33.5%) plumes associated with cRORA were congruent with the local normal

HFL and 25/129 (19.3%) were incongruent, with 16/129 (12.4%) of incongruent plumes

located at the cRORA border. In contrast, all 6/129 (4.7%) plumes associated with

iRORA were congruent with the HFL. Finally, 50/129 (38.8%) of plumes were not

associated with either cRORA or iRORA.

Laboratory study

To molecularly characterize cells corresponding to HRF, in the context of overall RPE

perturbation in AMD, we first used *ex vivo* OCT imaging to find human donor eyes with

AMD (fig. S6) and then confirmed diagnosis with histology. HRF found in OCT B-scans

of the macula were matched with pigmented cells in the subretinal space and retina of

stained sections (fig. S6). Atrophic AMD eyes with RPE plume in OCT exhibited

pigmented cells in the outer nuclear layer (ONL) and HFL on histology (fig. S6, C1 to C2

and F1 to F2). Twenty eyes of white donors (mean age 89.2 ± 5.0 years; 16 AMD, 4

control), with mean time from death to preservation of 3.9 ± 0.7 hours (table S5), were

studied.

To elucidate the molecular repertoire of abnormal RPE, including "sloughed" and

"intraretinal" phenotypes corresponding to HRF, we provide immunohistochemical

evidence for both gain-of-function and loss-of-function using antibodies for retinoid- and

immune-related proteins detailed in table S6 and appropriate positive and negative

controls in human tissues shown in fig. S7. To contextualize staining, we checked the

immunolabeling of all phenotypes (25) (table S7) using bright field microscopy for direct

observation of cellular pigmentation and status of surrounding tissue.

We begin by demonstrating that cells of RPE origin label with antibodies against

two well-known immune cell markers, Cluster of Differentiation (CD)68 and CD163 (26).

CD68 is a transmembrane glycoprotein that is abundantly expressed by macrophages

and widely used as a myeloid-specific marker (27). CD68 is one member (LAMP-4) of a

5-protein family that together accounts for 50% of the protein in lysosome membranes

(27). In human chorioretinal tissue sections Fig. 3, positive controls for CD68

immunoreactivity are choroidal macrophages (Fig. 3D) and negative controls are healthy

RPE (Fig. 3A). Fully pigmented cells in the neurosensory retina are strongly CD68+ (Fig.

3F). Importantly, individual sloughed cells in the subretinal space (Fig. 3C and 3F) are

also positive, as are individual cells still within the layer (Fig. 3E). Dissociated RPE

scattered in the atrophic area are universally labeled (Fig 3H and 3N), as are cells under

the continuous layer (Fig. 3I), and within outer retinal tubulation (Fig. 3J and 3K), i.e.,

tubes of scrolled photoreceptors (28). Some bilaminar (Fig. 3D) and melanotic (Fig. 3M)

cells are CD68+.

CD163 is a high-affinity haptoglobin-hemoglobin scavenger found in bone marrow-

derived macrophages (*29*) and in retinal cells resembling microglia (*30-32*). The latter

are phagocytes of embryologic yolk sac origin that reside in inner retina when quiescent

and migrate into outer retina when photoreceptors are damaged (*30*). Fig. S8 shows that

anti-CD163 labels inner retina cells but not the normal RPE layer, as expected. It does

label abnormal RPE phenotypes in a pattern like that of CD68, with overall lighter

reaction product. These include fully pigmented CD163+ cells in the ONL (fig. S8, F and

N), HFL (fig. S8L), above (fig. S8, E and I) and below (fig. S8I) the continuous RPE layer

in the subretinal and sub-RPE-basal laminar spaces, respectively, and dissociated cells

in atrophic areas (fig. S8, H, J and K).

Next, we show that abnormal RPE cells cease to express detectable quantities of

retinoid processing proteins. We begin with RPE65, the isomerohydrolase of the classic

visual cycle. RPE65 catalyzes the conversion of retinyl esters to 11-cis-retinol, which is

subsequently oxidized to 11-cis-retinal, required for visual transduction by rod and cone

photoreceptors (*33*). Figure 4 shows that in AMD eyes, intraretinal RPE in ONL (Fig. 4F)

and individual sloughed cells overlying the continuous layer (Fig. 4, C and L) lack

RPE65-immunoreactivity. Cells in areas of photoreceptor degeneration and depletion

are also RPE65-, including dissociated (Fig. 4N), subducted (Fig. 4I) and entubulated

(Fig. 4J) cells. Importantly, some individual cells in the continuous layer are RPE65-

(Fig.4, F and H). Interestingly some bilaminar cells within fibrotic scars of neovascular

AMD remain RPE65+ (Fig. 4M).

Cellular retinal binding protein (CRALBP), in addition to participating in the RPE-

based visual cycle, is also expressed by Müller glia in a second visual cycle supplying

only cones (*8, 34*). CRALBP is a 36-kDa water-soluble protein with 2 conformational

states facilitating intracellular transport of hydrophobic 11-cis retinoids (*35*). Fig. 5 shows

that healthy RPE has a strong CRALBP signal (Fig. 5A) as do Müller glia (Fig. 5E). In

AMD, ectopic RPE in the ONL, recognizable by pigmentation and granule load, are

CRALBP- (Fig. 5F and L). Individual sloughed cells (Fig. 5, H and L) and cells in the

continuous layer (Fig. 5E) are also negative as are pigmented cells in atrophic areas

(dissociated, Fig. 5, C, K and N; subducted, Fig. 5I). Shed granule aggregates (*18, 36*)

are CRALBP- under a CRALBP+ layer (Fig. 5B). Regardless of the degree of

photoreceptor loss (Fig. 5, C, J, K and N), Müller glia remain strongly CRALBP+ in their

cross-retinal course. This includes the external limiting membrane, i.e., junctional

complexes between glia and photoreceptors (*37*). In the HFL stained Müller glia are

parallel and straight in areas of lesser disease involvement (ordered (*10*), Fig. 5L). At the

border of atrophy (descent of the external limiting membrane (*38*), Fig. 5, C, K and N)

and outer retinal tubulation (Fig. 5J), CRALBP+ fibers curve down towards Bruch's

membrane and then head laterally, parallel to it. In some locations immunolabeled fibers

zig-zag in parallel, presenting cross-sections of dots and lines (disordered (*10*), Fig. 5, F

and N). CRALBP signal also appears in fibrotic scars resulting from neovascular AMD

(Fig. 5, D, G and M).

The number of stained cells in each RPE phenotype was assessed a semi-

quantitatively (0, not stained; 1, some cells of a phenotype stained; 2, all cells stained).

These scores were summed and expressed as a percent of the highest possible score,

as if all phenotypes had been stained completely by each antibody. Figure S9A shows

that the RPE phenotypes seen in these 16 AMD eyes were found in all the immuno-

stained sections. Figure S9B graphically summarizes the marker studies. Age-normal

uniform and non-uniform RPE is positive for retinoid markers and negative for immune

markers. Abnormal RPE phenotypes have overall less retinoid immunoreactivity

(although some stained cells were found) and universally more immune marker

immunoreactivity. Thus, cells corresponding to HRF in OCT are part of an overall pattern

of transdifferentiation resulting in gain-of-function and loss-of-function of RPE.

Our clinical study indicated that RPE plume like other OCT features in AMD has a

lifecycle. We previously showed in type 3 (intraretinal) neovascularization that RPE cells

contact the deep capillary plexus, suggesting ischemia due to choroidal insufficiency as

a precipitating event to anterior migration (*21*). We thus examined the trajectory of plume

cells at higher detail (Fig. 6). In Fig. 6, A to C, RPE cells in a plume are seen crossing

the HFL to approach and encircle capillaries of the deep plexus. Cells are nucleated and

contain numerous RPE-characteristic spindle-shaped melanosomes and

melanolipofuscin granules, in processes that extend along the capillaries (Fig. 6D).

We previously showed RPE organelles in the HFL of photoreceptor-depleted

atrophic areas (*10*), suggesting that Müller glia ingested and cleared debris from

degenerating RPE. Here we show region-specific distribution of RPE organelles,

consistent with the local trajectory of Müller glia. In the macula, Müller glia are Z-shaped

(*39*), because obliquely oriented fibers in the HFL verticalize at the border of OPL and

inner nuclear layer (fig. S2). In plumes near the fovea (Fig. 6, E and F; and fig. 8N), fully

pigmented RPE cells cross the obliquely oriented HFL, with individual and grouped

organelles in the lead. The path turns vertically to enter and cross the INL and IPL,

taking a Z-shaped course. In contrast, in the peripheral retina, where Müller glia are

vertical, fig. S10 shows melanosomes following a vertical track away from the RPE

above a druse.

DISCUSSION

Widespread clinical use of OCT has enabled visualization of smaller and thus earlier

stages of RPE pathology than the pigmentary changes known from color fundus

photography to confer progression risk (*40*). HRF are one of four OCT indicators in a

composite risk score for AMD progression risk (with soft and calcified drusen, plus

subretinal drusenoid deposit) (*41*). HRF confer the largest risk of these four indicators

(odds ratio, 5.21 (3.29-8.26) at 24 months))(*16*) and are the last to receive histologic

investigation. For RPE plume, an HRF with specific morphologies and behavior, we

establish a lifecycle including both cRORA and resolution without cRORA. We further

show that cells corresponding to HRF (sloughed and intraretinal) are two of many

abnormal RPE phenotypes undergoing molecular transdifferentiation in AMD.

Our parallel findings of CD68 and CD163 immunoreactivity in all abnormal RPE

phenotypes adds important new information to a decades-old debate (*42*) about whether

RPE, a phagocyte itself, shares or assumes properties of other phagocytes. This

investigation like our previous studies used high resolution comprehensive microscopy

to link cells with characteristic RPE organelles (*18, 19*) to a time course of activity visible

through longitudinal clinical imaging. Our cellular phenotyping system (*18*) built on prior

literature and is used by others (*43, 44*). We posited that these phenotypes represented

discrete steps towards death, migration, or transdifferentiation of individual cells that

could be followed over time in OCT due to high RPE reflectivity. In prior electron

microscopic analysis of pigmented cells corresponding to HRF (*45*), we did not observe

phagolysosomes, i.e., cytoplasmic vacuoles formed by phagosomes with ingested

material fusing with lysosomes, as expected from phagocyte activity. In a separate study

of HRF over a large drusenoid pigment detachment (*20*), all HRF could be attributed to

fully pigmented and nucleated intraretinal cells. In clinical cases of that prior study (*20*),

HRF appeared in the retina vertically above and several months after disturbances of the

RPE layer. Our current data further show that individual in-layer cells and all abnormal

phenotypes exhibit CD68 and CD163 immunoreactivity. We cannot entirely exclude the

possibility that phagocytes ingest and retain characteristic RPE organelles, seamlessly

intercalate into the layer, and either become abnormal phenotypes or induce them.

However, extensive transdifferentiation in response to common perturbations is also a

parsimonious explanation.

We emphasize that detection of CD68, a lysosomal protein of unknown function

reliably found in macrophages of myeloid origin (*27*), at one time point does not indicate

that immunoreactive pigmented cells have assumed macrophage behavior. Our data do

not imply that macrophages of hematopoietic origin previously documented in choroid

and sub-RPE-BL space (*46, 47*) actually started as RPE. Our data do not bear on the

identity of CD68+ cells seen by others, e.g., high-passage cultured RPE (*48*) and

surgically excised neovascular membranes (*49, 50*). Following experimental laser-injury

and rapid preservation, individual detached cells atop an intact RPE layer are CD68+

(*51*) resembling Fig. 3C and fig. S8C. Recent authors interpreted CD68+ cells in

aqueous after RPE tear (*52*) and in proliferative vitreoretinopathy (*53*) as RPE. A layer of

CD68+ cells in the outer junctional zone of atrophy in AMD was demonstrated by

immunofluorescence and laser confocal microscopy (*43*). This technique does not

directly reveal melanin, and the authors did not comment on cellular identity (*43*).

Our data further illuminate subducted cells on the inner collagenous layer of

Bruch's membrane, containing RPE organelles and originally called "spent RPE" (*54*). In

prior studies of single continuous high-resolution histologic sections of eyes with

cRORA, we saw plausible transitional morphologies between fully pigmented RPE

outside atrophic areas and flattened cells with fewer organelles in the sub-RPE-BL

space (*19*). We thus hypothesized that dissociated RPE in the central atrophic area,

loosed from constraining junctional complexes, dove under the layer and moved laterally

(*55*) into the outer junctional zone (*19*). Herein we show CD68+ and CD163+ cells and

highly pigmented RPE65- and CRALBP- cells in the same sub-RPE-BL tissue

compartment of the same eyes. Definitive multi-label immunohistochemistry is needed to

confirm whether these are all RPE-derived subducted cells. Further, the narrow sub-

RPE-BL space is known to contain macrophages of myeloid origin, multinucleate giant

cells, and fibroblasts (*56*). It is possible that co-localized CCR2 and CD18

immunoreactivity in these locations, attributed to macrophages (*57*), may represent

subducted and dissociated RPE, respectively. A plausible progression sequence based

on cellular phenotype and longitudinal imaging (fig. S1) offers a perspective on lineage

tracing independent of molecular marker snapshots (*57*).

A spreading outward of subducted cells may contribute to atrophy expansion

beyond degeneration of RPE and photoreceptors and gliosis. Macrophages that co-

express CD68 and CCR7 can be assigned to a ''proinflammatory'' M1 subset, whereas

CD68+ CD163+ macrophages most likely belong to an ''anti-inflammatory'' M2 subset

(*58*). Longitudinal studies with next-generation high-resolution OCT (*59, 60*) may allow

tracking of subducted cells to see if they promote or retard atrophy expansion. Such

information will be highly valuable, because expansion is the only regulatorily-approved

anatomic endpoint for clinical trials.

Our expectation of plume congruence with HFL trajectory was largely met and of

note was non-congruence near cRORA (table S4). This is likely due to subsidence

(sinking) of the OPL, HFL, and ONL, a committed step toward cRORA onset (*61*).

Subsidence is visible where photoreceptors focally shorten and are scrolled by Müller

glia (*10, 62*). Our data on plume trajectories and CRALBP immunohistochemistry thus

add to prodigious activities of Müller glia in AMD. These include descent and curving of

the ELM (border of atrophy), reactive gliosis, adherent glial seal in areas of

photoreceptor depletion, and invasion of individual drusen (*28, 38, 63, 64*). Parallelism of

HFL fibers contributes to high light transmittance in healthy retina; HFL reflectivity

increases focally when disturbed (*65, 66*). CRALBP immunohistochemistry confirmed

HFL fiber geometry as well as retinoid capacity of Müller glia, still supported by retinal

circulation late in disease. Single and grouped RPE organelles paralleling Müller glia

(*10, 67*) are presumably carried intracellularly. In contrast RPE cell bodies traveling

between HFL fibers (Fig. 5L and Fig. 6) following a trail of organelle detritus. Active glial

disassembly and removal of fragments is suspected.

Because almost 40% of plumes were not associated with atrophy at follow-up

(table S4), plumes should be considered indicators not predictors. Factors underlying

variable plume outcome in our study include inclusion of patients with established

disease, short observation period, and a "come and go" behavior consistent with cells

subject to constant pro-migratory stimuli being dismantled *en route*. Given our evidence

for widespread transdifferentiation, HRF including plumes may indicate risk by revealing

an overall level of disease activity not only in the RPE layer but also in less-visible

adjacent tissue layers (e.g., drusen-associated lipid peroxidation in the sub-RPE-BL

space, Bruch's membrane cross-linking, loss of choriocapillary endothelium (*68-70*)).

These collectively impair bi-directional exchange between outer retina and the circulation

and introduce pro-inflammatory, pro-angiogenic compounds. A major role for ischemia

due to vascular insufficiency is underscored by evidence for RPE cells contacting retinal

capillaries (Fig. 6; (20, 21)). Our demonstration of fully pigmented plume cells aiming

towards and clustering around the deep capillary plexus (Fig. 6) further supports the idea

that the cells are RPE in transit and not phagocytes. They apparently move as a

coordinated group rather than as single cells that go to vessels and proliferate. Similar

conclusions about an inductive role of vascular insufficiency have been reached for

neovascularization of choroidal origin (71). Finally, a visual task limited by retinoid

resupply from the circulation (7), rod-mediated dark adaptation, is the earliest affected

and most persistent visual dysfunction in AMD (6, 72). Loss of RPE65 and CRALBP

immunoreactivity (without appearance of lipid droplets as in RPE65 deficiency (73))

suggests overall downregulation of a signature RPE function.

Our marker studies indicating RPE gain- and loss-of-function have implications for

therapeutic strategy. Molecular discovery in AMD is challenged by strong RPE

pigmentation and autofluorescence and the availability of donor eyes. Our finding of

reduced CRALBP immunoreactivity in abnormal RPE differs from a report of increased

CRALBP seen by 2-D gel electrophoresis (74). In the outer junctional zone of atrophy,

we previously showed vimentin immunoreactivity in enlarged RPE (75), suggestive of

epithelial-mesenchyme transition, and recently supported by increased Snail1 and

vimentin and decreased E-cadherin proteins in AMD eyes (76, 77) Cells in this transition

might be resistant to cell death, considered a positive feature (76), but they may also be

dysfunctional, according to our data. Other molecular RPE changes reported in AMD

(e.g., (44, 74, 78-81) are not yet localized to phenotypes translatable to clinical imaging.

Our evidence for molecular alteration in intact continuous RPE comports with re-

arrangement and loss of lipofuscin-attributable autofluorescence in geometrically precise

confluent cells (*82*). Therefore, a search for early interventions and preventative

measures for AMD is warranted.

Strengths of the clinical study are high-quality images and long follow-up on known

progression risk factors. Limitations include the small number of patients and lack of

independently assessed HFL trajectory. Strengths of the laboratory study are short post-

mortem specimens with attached retinas, comprehensive bright-field photomicroscopy to

visualize pigment, a color-contrasting readout for clear immunoreactivity signals, and a

cross-sectional format conducive to OCT comparison. Limitations include lack of clinical

records with pre-mortem imaging, lack of correlative data from flat mounts to show even

earlier RPE pathology, limited assessments of RPE adjacent to AMD deposits, and lack

of double-label experiments to determine cell-by-cell overlap among the four markers.

Nevertheless, this is most detailed characterization of RPE pathology in AMD to date in

either clinical or laboratory settings. HRF are one of the consensus OCT features for

AMD (*13*), encouraging longitudinal studies in other clinical centers. Our data can propel

new biomarker and therapeutic strategies for a common and currently untreatable cause

of impaired vision.

MATERIALS AND METHODS

Study design, clinical imaging

Compliance

Study of a clinical cohort and use of human tissue samples was approved by institutional

review board at Vitreous Macula Retina and University of Alabama at Birmingham,

respectively, and complied with the Health Insurance Portability and Accountability Act of

1996 and the Declaration of Helsinki.

Patient selection, clinical image capture, and image analysis

Consensus OCT nomenclature was used (*83*) in the context of a 3-layer Bruch's

membrane (*84*). The term RPE-basal lamina (RPE-BL) band was used for RPE

elevations from the inner collagenous layer of Bruch's membrane.

To analyze RPE plume natural history, patients with non-neovascular AMD on

OCT imaging seen by retinal specialist (authors KBF, LAY) at a tertiary private retinal

practice were retrospectively reviewed (author BL). Inclusion criteria included age over

50 years, more than 12 months of follow-up with tracked OCT B-scans at an inter-scan

spacing of ≤250 μm and maximum follow-up interval of 6 months, and at least one eye in

which HRF separated from and thought to originate from the RPE layer (i.e., if RPE-BL

thickness appeared reduced in a scan subsequent to HRF appearance). Patients with

diabetic retinopathy, retinal vascular disease, previous vitreoretinal surgery, laser

treatment or ocular inflammation were excluded. Eyes were evaluated at baseline by

presence of AMD lesions (soft, cuticular, subretinal drusenoid deposits, acquired

vitelliform lesion (*24*)), and if color fundus photographs were available, also pigmentary

changes. Presence of drusenoid pigment epithelial detachment (*85*) and cRORA (*12*)

was noted.

All patients underwent spectral domain OCT and near-infrared reflectance imaging

(Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany) with eye

tracking enabled. The OCT protocol comprised 20° horizontal raster line scans centered

on the fovea (19 to 49 B-scans per eye; scan spacing at 115 to 250 µm, automatic real-

time averaging between 4 and 23).

Consecutive tracked OCT and near-infrared reflectance images were analyzed

over time and with reference to the foveal center, from the date of HRF appearance.

Plume morphology over time included nil change, change to a different morphology,

formation of an HRF with discrete reflective elements clearly separated from the RPE-BL

band, and dissolution. With the knowledge of the normal HFL architecture (fig. S2),

plume direction towards the OPL was noted as being congruent or incongruent with a

normal HFL architecture, i.e., parallel or non-parallel with curving fibers. Evolution of

underlying AMD pathology such as expansion of cRORA and drusen growth and

collapse were noted.

Donor eye acquisition, ex vivo imaging, AMD diagnosis

Whole eyes were obtained from deceased human donors (≥ 80 years of age, white, non-

diabetic, and ≤6 hours death-to-preservation) to the Advancing Sight Network

(Birmingham AL USA) during 2016-17. Pre-mortem eye health history was not available.

Eyes were preserved in 4% buffered paraformaldehyde and screened for AMD presence

and stage using *ex vivo* multimodal imaging including OCT, as described, (*20*) and

stored in 1% buffered paraformaldehyde at 4°C until used. This study used 16 AMD

eyes (7 early-intermediate AMD, 6 atrophic AMD, 3 neovascular AMD) and 4 age-

matched control eyes (table S5).

Rectangles of full-thickness eye wall (5x8 mm) including fovea and optic nerve

were dissected. To prevent ice crystals, tissue was cryoprotected in ascending

concentrations of sucrose in phosphate buffered saline (PBS) then ascending

concentrations of tissue embedding medium and sucrose buffer (HistoPrep, Thermo

Fisher Scientific, #SH75-1250D, Rockford IL USA); 4 parts sucrose buffer and 1part

medium then 2:1 sucrose: medium. Tissue was placed into a cryomold (Electron

Microscopy Sciences, #70176-10, Fort Washington PA USA) with embedding medium,

oriented, frozen in liquid nitrogen, and stored at -80°C. Tissues were sectioned at 12 µm

thickness on a cryostat (Leica CM3050 Vashaw Scientific, Norcross GA USA), air dried

at 37°C overnight, and stored at -80°C until used.

For AMD diagnosis and imaging-histology correlation, cryosections through the

fovea and perifovea (recognized by HFL) were stained with periodic acid Schiff

hematoxylin to highlight Bruch's membrane and sub-RPE deposits. One stained section

per slide was scanned with a 20X objective and a robotic microscope stage (Olympus

VSI 120, CellSens; Olympus, Center Valley PA), scaled to tissue units, and centered on

the fovea or vertical meridian (where Henle fibers diverge) using a custom plugin for FIJI

(https://imagej.nih.gov/ij/download.html). *Ex vivo* OCT B-scans and scanned whole

sections were matched for major landmarks (e.g., overall tissue contour, foveal center,

large vessels, individual pathologies). For figures, images were adjusted to maximize the

intensity histogram for contrast and white balance and made into composites

(Photoshop CS6, Adobe Systems, USA).

Immunohistochemistry and evaluation

Markers for retinoid activity and immune function were localized in cells of RPE origin

(*86*) sections processed with an avidin-biotin-peroxidase immunohistochemistry

detection system and antibodies list in table S6. Cryosections were warmed, hydrated in

PBS at room temperature, and processed for 15 minutes under steam with an antigen

retrieval solution (Vector Labs, #H-3300-250) in glycerol. Quenched endogenous

hydrogen peroxide with 3% H_2O_2 diluted from 30% H_2O_2 (Thermo Fisher Scientific

Cat# H-325-100) with distilled H_2O for ten minutes at room temperature (except for

CD68 after primary antibody as manufacture mentioned). Non-specific binding was

blocked with 5% horse serum for 1 hour at room temperature, then incubated with

primary antibodies of mouse anti-CD68, CD163, RPE65, or CRALBP at 4ºC for 40

hours. Following PBS wash, sections were incubated with avidin and biotin solutions for

15 minutes respectively, washed (x3), then incubated with horse anti-mouse secondary

antibody (Vector Labs Vectastain Elite ABC Kit RTU Universal, #PK-7200) for 4 hours at

room temperature, washed (x3), and incubated with ABC complex solution (Vector Labs

Vectastain Elite ABC Kit RTU Universal, #PK-7200) for 30 minutes at room temperature,

and washed. A red reaction product was developed with Vector AEC Peroxidase

Substrate Kit (Vector Labs, Burlingame CA USA #SK-4200) to the desired color (~30

minutes). After washing with distilled water (5 minutes x 3), sections were counterstained

with hematoxylin solution for 5 minutes followed by 20 seconds bluing solution (Poly

Scientific R&D Corp, Bay Shore NY USA; #S127-160Z) then washed. Coverslips were

mounted with aqueous medium (VectaMount AQ, Vector Labs, #H-5501-60) and sealed

with nail polish, air-dried, and stored at 4ºC. As shown in fig. S7, we used isotype-

specific negative controls (mouse antibodies), sham controls omitting primary antibody,

and external and internal positive controls.

Glass slides were scanned using the system described above and 20x and 40x

objectives. RPE phenotype was categorized using the Project MACULA grading system.

(*18, 19*) In each stained section (1 per antibody per eye), immunoreactivities for each

RPE phenotype were scored semi-quantitatively by a single observer (author DC after

training by author CAC) as 0-not stained, 1-some stained and 2- all stained. These

scores were converted to percentages (fig. S9) using by total scores of eyes for each

phenotype divided by maximum score (2 x number of eyes with the phenotype) times

100. Each phenotype was seen in at least 3 eyes.

SUPPLEMENTARY MATERIALS

Supplementary figures

Fig. S1. A path from hyperreflective foci (HRF) to complete retinal pigment epithelium

(RPE) and outer retinal atrophy (cRORA) in AMD.

Fig. S2. Henle fibers in the human macula.

Fig. S3. Retinal pigment epithelium plumes exhibit directionality

Fig. S4. Duration and evolution of plumes

Fig. S5. Variations in RPE plume trajectory in atrophy.

Fig. S6. HRF in ex vivo OCT match intraretinal RPE on histology

Fig. S7. Positive and negative controls for immunohistochemistry

Fig. S8: RPE corresponding to HRF and other abnormal cells are CD163+

Fig. S9. Gain- and loss-of-function of RPE and RPE-derived cells

Fig. S10. Dispersing melanosomes follow regionally specific trajectories of Müller glia

Supplementary tables

Table S1. Demographics of clinic patients

Table S2. Plume disposition at final visit

Table S3. Plume trajectory relative to HFL and macular quadrant

Table S4. Plume association with atrophy

Table S5. Characteristics of donor eyes

Table S6. Antibodies used

Table S7. Morphologic phenotypes of RPE and its basal lamina in AMD

Acknowledgments

We thank Advancing Sight Network (formerly the Alabama Eye Bank) for timely retrieval

of donor eyes and David Fisher for graphics in Supplementary Figure 1.

Funding

This work was supported by National Institutes of Health (Bethesda, MD, USA) grant

R01EY015520 (CAC); The Macula Foundation, Inc., New York, NY; an anonymous

donor to AMD research at UAB; unrestricted funds to the Department of Ophthalmology

from Research to Prevent Blindness, Inc.; and EyeSight Foundation of Alabama.

Acquisition of human tissues for immunohistochemistry was funded by NIH grant

R01EY015520 (CAC) and R01EY027948 (CAC, TA) and IZKF Würzburg (N-304, TA).

Author contributions

C.A.C. designed, supervised study and wrote the manuscript. D.C. designed and

performed immunohistochemistry experiments. B.L. designed and conducted clinical

studies and wrote the manuscript. J.M. conducted *ex vivo* imaging, tissue cryosections,

and microscopy. D.K. made Fig. S2. T.A. edited manuscript. L.A.Y. and K.B.F designed

and supervised clinical study. K.B.F. edited manuscript. C.A.C. and T.A. raised funding.

Competing interests

T.A. receives research funding from Novartis and is a stockholder of MacRegen Inc.

K.B.F. is a consultant to Genentech, Optovue, Zeiss, Heidelberg Engineering, Allergan,

and Novartis. C.A.C. receives research funds from Genentech/ Hoffman LaRoche and

Heidelberg Engineering and is a stockholder of MacRegen Inc.

Data and materials availability

All other data associated with this study are present in the paper or the Supplementary

Materials. Materials are available upon request from the corresponding author.

Figures and Captions

Fig. 1. **Morphology of retinal pigment epithelium plumes.**

Examples from two eyes of one patient. (**A**) "Curvilinear" consists of hyperreflective

structures of consistent width, often arising from a soft druse and aiming towards the

outer plexiform layer. (**B**) "Thread" has a uniform and thin width, compared to

Curvilinear. (**C**) "Comma" has a wide base adjacent to the RPE layer and an anterior

taper. (**D**) "Vitelliform" is thick and arises from an acquired vitelliform lesion (*24*).

Fig. 2. **Retinal pigment epithelium plumes evolve over time.**

(**A** to **E**) Tracked optical coherence tomography B-scans of 5 different eyes with AMD

are shown with individualized colored frames and scale bars. Numbers in the lower right

corners indicate time elapsed in months since the baseline visit at 0 months. (**A1** to **A4**)

Hyperreflective foci (HRF) overlie a drusenoid pigment epithelial detachment that

collapsed at 12 months. HRF evolve into a comma plume before disappearing into

complete outer retinal atrophy (cORA (*12*)). (**B1** to **B6**) A curvilinear plume evolves into a

vitelliform plume, which collapses, leaving atrophy and degenerative cysts. (**C1** to **C3)** A

comma-type plume evolves into HRF upon drusen collapse. (**D1** to **D3**) Of two thread

plumes at baseline, one (left) becomes curvilinear at 3 months and persists through

drusen collapse and *incomplete* RPE and outer retinal atrophy at 13 months. Thread

plume at the right has disappeared at 13 months. (**E1** to **E2)**. Two thread plumes evolve

into a comma plume as an RPE elevation appears. This eye also has an epiretinal

membrane.

Fig. 3. RPE corresponding to HRF and other abnormal cells are CD68+.

Twenty donor eyes (16 AMD, 4 control; eye numbers in table S5) were used for

immunohistochemistry with mouse monoclonal anti-human CD68 (table S6). Fourteen of

16 previously described morphologic phenotypes of RPE (*25*) were identified (table S7).

All scale bars are 20 µm; yellow arrowheads indicate BrM, and green arrowheads

indicate abnormal phenotypes. (**A**) CD68- "Uniform" RPE, unremarkable (#1). (**B**) CD68-

granule aggregates, released basally from "Shedding" RPE; atrophic AMD (#13). (**C**)

CD68+ "Sloughed" RPE; atrophic AMD (#12). **D.** Both CD68+ and CD68- "Entombed"

RPE; nvAMD (#18). (**C**) A single CD68+ "Nonuniform" RPE from a less-affected area,

nvAMD (#20). (**F**) CD68+ "Intraretinal" RPE; early-intermediate AMD (#7). (**G**) Variable

CD68 immunoreactivity in "Melanotic" RPE, nvAMD (#18). CD68 immunoreactivity is

variable on heavily and light pigmented melanotic RPE. **H.** CD68+ "Severe" RPE;

atrophic AMD (#13). (**I**) CD68+ "Subducted" RPE, atrophic AMD (#12). (**J**) CD68+

"Entubulated" RPE, atrophic AMD (#12). (**K**) CD68+ "Dissociated" RPE, atrophic AMD

(#12). (**L**) CD68+ "Dissociated" RPE and "Sloughed" RPE, early-intermediate AMD (#7).

582 (**M**) Variable CD68 immunoreactivity in ''Bilaminar'' RPE, nvAMD (#20). (**N**) CD68+

583 "Dissociated" RPE; atrophic AMD (#12).

Fig. 4. RPE corresponding to HRF and other abnormal cells are RPE65-.

Twenty donor eyes (16 AMD, 4 control; eye numbers in table S5) were for

immunohistochemistry with mouse monoclonal anti-human RPE65 (table S6). Fourteen

of 16 previously described morphologic phenotypes of RPE were identified (table S7). All

scale bars are 20 μm; yellow arrowheads indicate BrM; green arrowheads indicate

abnormal RPE phenotypes. (**A**) RPE65+ "Uniform" RPE, unremarkable (#1). (**B**) RPE65-

"Shedding" RPE, nvAMD (#20). (**C**) RPE65- "Sloughed" RPE, atrophic AMD (#13). (**D**)

Both RPE65+ and REP65- "Entombed" RPE, nvAMD (#18). (**E**) A few RPE65-

"Nonuniform" RPE, early-intermediate AMD (#6). (**F**) RPE65- "Intraretinal" RPE, early-

intermediate AMD (#11). (**G**) Variable RPE65 immunoreactive "Melanotic" RPE, nvAMD

(#18). (**H**) RPE65- "Severe" RPE, atrophic AMD (#12). (**I**) RPE65- "Subducted" RPE,

atrophic AMD (#12). (**J**) Both RPE65+ and RPE65- "Entubulated" RPE, atrophic AMD

(#12). (**K**) RPE65- RPE at "Atrophy without BLamD" area, atrophic AMD (#12). (**L**)

RPE65- "Dissociated" RPE, atrophic AMD (#16). (**M**) Both RPE65- and RPE65+

''Bilaminar'' RPE, nvAMD (#20). (**N**) RPE65- RPE at ''Atrophy with BLamD'' area,

atrophic AMD eye (#13).

Fig. 5. Abnormal RPE is CRALBP-, Müller glia are CRALBP+.

Twenty donor eyes (16 AMD, 4 control; eye numbers in table S5) were used for

immunohistochemistry with mouse monoclonal anti-human CRALBP (table S6).

Fourteen of 16 previously described morphologic phenotypes of RPE were identified

(table S7). All scale bars are 20 µm. Yellow arrowheads indicate BrM. Green

arrowheads indicate abnormal phenotypes including migrating RPE corresponding to

HRF. (A) CRALBP+ "Uniform" RPE, unremarkable (#1). (B) CRALBP- ''Shedding'' RPE,

early-intermediate AMD (#6). (C) CRALBP- ''Sloughed'' RPE, atrophic AMD (#13). (D)

Both CRALBP+ and CRALBP- ''Entombed'' RPE nvAMD (#18). (E)CRALBP-

"Nonuniform" RPE nvAMD (#18). (F) CRALBP- ''Intraretinal'' RPE, early-intermediate

AMD eye (#7). (G) Both CRALBP+ and CRALBP- ''Melanotic'' RPE, nvAMD (#18). (H)

CRALBP- "Severe" RPE, atrophic AMD (#12). (I) CRALBP- ''Subducted'' RPE, atrophic

AMD (#12). (J) Both CRALBP+ and CRALBP- ''Entubulated'' RPE, atrophic AMD (#12).

(K) CRALBP- RPE at ''Atrophy without BLamD'' area, atrophic AMD (#12). (L) CRALBP-

"Dissociated" RPE, early-intermediate AMD (#7). (M) Variable CRALBP

immunoreactivity in ''Bilaminar'' RPE, nvAMD (#20). (N) Variable CRALBP+ and

CRALBP- RPE at ''Atrophy with BLamD'' area, nvAMD (#7).

Fig. 6. RPE migrate toward vessels and follow Müller glial columns.

One eye from each of two donors aged 86-90 years (#5 and #15, table S5) were

subjected to *ex vivo* OCT images in A (fig. S6, C1 and C2) and PASH staining with

cryosections in B, E and F. (**A**) *Ex vivo* OCT of donor eye (#5) shows HRF (yellow

arrowhead) over a large druse. (**B**) Corresponding PASH histologic section 290 µm

superior to the fovea with a big druse (d), artifactually detached (x) from the RPE, and

thinner ONL. (**C**) Magnified RPE rosette in B (yellow arrowheads) crossing the HFL and

approaching retinal capillaries (green arrowheads). (**D**) Nucleated RPE rosette from

panel C (adjacent section). RPE-characteristic spindle-shaped melanosomes and

melanolipofuscin impart a brown hue. The surrounded capillary is stained light pink

(green arrowhead) with endothelial cell nuclei. Processes containing RPE organelles

extend along the capillaries. (**E** and **F**) In another plume, RPE cells and detritus take a Z-

shaped course. Fully pigmented RPE cells cross the obliquely oriented fibers of the HFL,

with individual and grouped organelles in the lead (thin yellow arrows). The path turns

vertically to enter and cross the INL and IPL.

References

1.   S. R. Flaxman, R. R. A. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite, M. V.
Cicinelli, A. Das, J. B. Jonas, J. Keeffe, J. H. Kempen, J. Leasher, H. Limburg, K.
Naidoo, K. Pesudovs, A. Silvester, G. A. Stevens, N. Tahhan, T. Y. Wong, H. R. Taylor,
S. Vision Loss Expert Group of the Global Burden of Disease, Global causes of
blindness and distance vision impairment 1990-2020: a systematic review and meta-
analysis. *The Lancet. Global health* 5, e1221-e1234 (2017).
2.   M. G. Maguire, D. F. Martin, G. S. Ying, G. J. Jaffe, E. Daniel, J. E. Grunwald, C.
A. Toth, F. L. Ferris, 3rd, S. L. Fine, Five-year outcomes with anti-vascular endothelial
growth factor treatment of neovascular age-related macular degeneration: the
Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*
123, 1751-1761 (2016).
3.   L. Chen, J. D. Messinger, D. Kar, J. L. Duncan, C. A. Curcio, Biometrics, impact,
and significance of basal linear deposit and subretinal drusenoid deposit in age-related
macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 62, 33 (2021).
4.   P. A. Keane, P. J. Patel, S. Liakopoulos, F. M. Heussen, S. R. Sadda, A. Tufail,
Evaluation of age-related macular degeneration with optical coherence tomography.
Surv Ophthalmol 57, 389-414 (2012).
5.   R. H. Guymer, P. J. Rosenfeld, C. A. Curcio, F. G. Holz, G. Staurenghi, K. B.
Freund, S. Schmitz-Valckenberg, J. R. Sparrow, R. F. Spaide, A. Tufail, U.
Chakravarthy, G. J. Jaffe, K. Csaky, D. Sarraf, J. M. Monés, R. Tadayoni, J. Grunwald,
F. Bottoni, S. Liakopoulos, D. Pauleikhoff, S. Pagliarini, E. Y. Chew, F. Viola, M.
Fleckenstein, B. Blodi, T. H. Lim, V. Chong, G. A. Lutty, A. C. Bird, S. R. Sadda,
Incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) in age-related
macular degeneration: CAM Report 4. *Ophthalmology* 127, 394-409 (2020).
6.   C. Owsley, G. McGwin, Jr., M. E. Clark, G. R. Jackson, M. A. Callahan, L. B. Kline,
C. D. Witherspoon, C. A. Curcio, Delayed rod-mediated dark adaptation is a functional
biomarker for incident early age-related macular degeneration. *Ophthalmology* 123, 344-
351 (2016).
7.   T. D. Lamb, E. N. Pugh, Jr., Phototransduction, dark adaptation, and rhodopsin
regeneration: the Proctor Lecture. *Invest Ophthalmol Vis Sci* 47, 5137-5152 (2006).
8.   J. C. Saari, Vitamin A and Vision. *Subcell Biochem* 81, 231-259 (2016).
9.   A. Pollreisz, M. Neschi, K. R. Sloan, M. Pircher, T. J. Mittermueller, D. M. Dacey,
U. Schmidt-Erfurth, C. A. Curcio, An atlas of human retinal pigment epithelium
organelles significant for clinical imaging. *Invest Ophthalmol Vis Sci* 61, 13 (2020).
10.   M. Li, C. Huisingh, J. D. Messinger, R. Dolz-Marco, D. Ferrara, K. B. Freund, C. A.
Curcio, Histology of geographic atrophy secondary to age-related macular degeneration:
a multilayer approach. *Retina* 38, 1937-1953 (2018).
11.   F. G. Holz, S. Sadda, G. Staurenghi, M. Lindner, A. C. Bird, B. A. Blodi, B. Bottoni,
U. Chakravarthy, E. Chew, K. Csaky, C. A. Curcio, R. Danis, K. B. Freund, J. Grunwald,
R. Guymer, C. Hoyng, G. J. Jaffe, S. Liakopoulos, J. Monés, A. Oishi, D. Pauleikhoff, P.
J. Rosenfeld, D. Sarraf, R. F. Spaide, R. Tadayoni, A. Tufail, S. Wolf, S. Schmitz-
Valckenberg, Imaging protocols for clinical studies in age-related macular degeneration
– recommendations from Classification of Atrophy (CAM) Consensus Meeting.
Ophthalmology 124, 464-478 (2017).
12.   S. R. Sadda, R. Guymer, F. G. Holz, S. Schmitz-Valckenberg, C. A. Curcio, A. C.
Bird, B. A. Blodi, F. Bottoni, U. Chakravarthy, E. Y. Chew, K. Csaky, R. Danis, M.

Fleckenstein, K. B. Freund, J. Grunwald, C. B. Hoyng, G. J. Jaffe, S. Liakopoulos, J.
Monés, D. Pauleikhoff, P. J. Rosenfeld, D. Sarraf, R. F. Spaide, R. Tadayoni, A. Tufail,
S. Wolf, G. Staurenghi, Consensus definition for atrophy associated with age-related
macular degeneration on optical coherence tomography: CAM Report 3. *Ophthalmology*
125, 537-548 (2018).
13. G. J. Jaffe, U. Chakravarthy, K. B. Freund, R. H. Guymer, F. G. Holz, S.
Liakopoulos, J. Monés, P. J. Rosenfeld, S. R. Sadda, D. Sarraf, S. Schmitz-
Valckenberg, R. F. Spaide, G. Staurenghi, A. Tufail, C. A. Curcio, Imaging features
associated with progression to geographic atrophy in age-related macular degeneration:
CAM Report 5. *Ophthalmology Retina* 12/20/20 online, (2020).
14. Y. Ouyang, F. M. Heussen, A. Hariri, P. A. Keane, S. R. Sadda, Optical coherence
tomography-based observation of the natural history of drusenoid lesion in eyes with dry
age-related macular degeneration. *Ophthalmology* 120, 2656-2665 (2013).
15. J. G. Christenbury, F. A. Folgar, R. V. O'Connell, S. J. Chiu, S. Farsiu, C. A. Toth,
Progression of intermediate age-related macular degeneration with proliferation and
inner retinal migration of hyperreflective foci. *Ophthalmology* 120, 1038-1045 (2013).
16. M. Nassisi, J. Lei, N. S. Abdelfattah, A. Karamat, S. Balasubramanian, W. Fan, A.
Uji, K. M. Marion, K. Baker, X. Huang, E. Morgenthien, S. R. Sadda, OCT risk factors for
development of late age-related macular degeneration in the fellow eyes of patients
enrolled in the HARBOR study. *Ophthalmology* 126, 1667-1674 (2019).
17. S. M. Waldstein, W.-D. Vogl, H. Bogunovic, A. Sadeghipour, S. Riedl, U. Schmidt-
Erfurth, Characterization of drusen and hyperreflective foci as biomarkers for disease
progression in age-related macular degeneration using artificial intelligence in optical
coherence tomography. *JAMA Ophthalmology* 138, 740-747 (2020).
18. E. C. Zanzottera, J. D. Messinger, T. Ach, R. T. Smith, K. B. Freund, C. A. Curcio,
The Project MACULA retinal pigment epithelium grading system for histology and optical
coherence tomography in age-related macular degeneration. *Invest Ophthalmol Vis Sci*
56, 3253-3268 (2015).
19. E. C. Zanzottera, J. D. Messinger, T. Ach, R. T. Smith, C. A. Curcio, Subducted
and Melanotic cells in advanced age-related macular degeneration are derived from
retinal pigment epithelium. *Invest Ophthalmol Vis Sci* 56, 3269-3278 (2015).
20. C. Balaratnasingam, J. D. Messinger, K. R. Sloan, L. A. Yannuzzi, K. B. Freund, C.
A. Curcio, Histologic and optical coherence tomographic correlations in drusenoid
pigment epithelium detachment in age-related macular degeneration. *Ophthalmology*
124, 644-656 (2017).
21. M. Li, R. Dolz-Marco, J. D. Messinger, L. Wang, R. M. Feist, C. A. Girkin, S.
Gattoussi, D. Ferrara, C. A. Curcio, K. B. Freund, Clinicopathologic correlation of anti-
vascular endothelial growth factor-treated type 3 neovascularization in age-related
macular degeneration. *Ophthalmology* 125, 276-287 (2018).
22. C. Jopling, S. Boue, J. C. Izpisua Belmonte, Dedifferentiation, transdifferentiation
and reprogramming: three routes to regeneration. *Nat Rev Mol Cell Biol* 12, 79-89
(2011).
23. J. R. Sparrow, M. Marsiglia, R. Allikmets, S. Tsang, W. Lee, T. Duncker, J.
Zernant, Flecks in recessive Stargardt disease: short-wavelength autofluorescence,
near-infrared autofluorescence, and optical coherence tomography. *Invest Ophthalmol*
Vis Sci 56, 5029-5039 (2015).

24.   K. B. Freund, K. Laud, L. H. Lima, R. F. Spaide, S. Zweifel, L. A. Yannuzzi,
Acquired vitelliform lesions: correlation of clinical findings and multiple imaging analyses.
Retina 31, 13-25 (2011).
25.   C. A. Curcio, E. C. Zanzottera, T. Ach, C. Balaratnasingam, K. B. Freund,
Activated retinal pigment epithelium, an optical coherence tomography biomarker for
progression in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 58, BIO211-
BIO226 (2017).
26.   M. H. Barros, F. Hauck, J. H. Dreyer, B. Kempkes, G. Niedobitek, Macrophage
polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages.
PLoS One 8, e80908 (2013).
27.   D. A. Chistiakov, M. C. Killingsworth, V. A. Myasoedova, A. N. Orekhov, Y. V.
Bobryshev, CD68/macrosialin: not just a histochemical marker. *Lab Invest* 97, 4-13
(2017).
28.   K. B. Schaal, K. B. Freund, K. M. Litts, Y. Zhang, J. D. Messinger, C. A. Curcio,
Outer retinal tubulation in advanced age-related macular degeneration: optical
coherence tomographic findings correspond to histology. *Retina* 35, 1339-1350 (2015).
29.   A. Etzerodt, S. K. Moestrup, CD163 and inflammation: biological, diagnostic, and
therapeutic aspects. *Antioxid Redox Signal* 18, 2352-2363 (2013).
30.   M. Karlstetter, R. Scholz, M. Rutar, W. T. Wong, J. M. Provis, T. Langmann,
Retinal microglia: just bystander or target for therapy? *Prog Retin Eye Res* 45, 30-57
(2015).
31.   E. M. Lad, S. W. Cousins, A. D. Proia, Identity of pigmented subretinal cells in age-
related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 254, 1239-1241
(2016).
32.   M. A. Margeta, E. M. Lad, A. D. Proia, CD163+ macrophages infiltrate axon
bundles of postmortem optic nerves with glaucoma. *Graefes Arch Clin Exp Ophthalmol*
256, 2449-2456 (2018).
33.   J. von Lintig, J. Moon, D. Babino, Molecular components affecting ocular
carotenoid and retinoid homeostasis. *Prog Retin Eye Res* 80, 100864 (2021).
34.   Y. Xue, S. Q. Shen, J. Jui, A. C. Rupp, L. C. Byrne, S. Hattar, J. G. Flannery, J. C.
Corbo, V. J. Kefalov, CRALBP supports the mammalian retinal visual cycle and cone
vision. *J Clin Invest* 125, 727-738 (2015).
35.   T. Liu, E. Jenwitheesuk, D. C. Teller, R. Samudrala, Structural insights into the
cellular retinaldehyde-binding protein (CRALBP). *Proteins* 61, 412-422 (2005).
36.   T. Ach, E. Tolstik, J. D. Messinger, A. V. Zarubina, R. Heintzmann, C. A. Curcio,
Lipofuscin re-distribution and loss accompanied by cytoskeletal stress in retinal pigment
epithelium of eyes with age-related macular degeneration. *Invest Ophthalmol Vis Sci* 56,
3242-3252 (2015).
37.   S. Omri, B. Omri, M. Savoldelli, L. Jonet, B. Thillaye-Goldenberg, G. Thuret, P.
Gain, J. C. Jeanny, P. Crisanti, F. Behar-Cohen, The outer limiting membrane (OLM)
revisited: clinical implications. *Clin Ophthalmol* 4, 183-195 (2010).
38.   E. C. Zanzottera, T. Ach, C. Huisingh, J. D. Messinger, R. F. Spaide, C. A. Curcio,
Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy
in age-related macular degeneration. *Retina* 36 Suppl 1, S12-S25 (2016).
39.   A. Matet, M. C. Savastano, M. Rispoli, C. Bergin, A. Moulin, P. Crisanti, F. Behar-
Cohen, B. Lumbroso, En face optical coherence tomography of foveal microstructure in
full-thickness macular hole: a model to study perifoveal Muller cells. *Am J Ophthalmol*
159, 1142-1151 e1143 (2015).

40.   F. L. Ferris, 3rd, C. P. Wilkinson, A. Bird, U. Chakravarthy, E. Chew, K. Csaky, S.
R. Sadda, Clinical classification of age-related macular degeneration. *Ophthalmology*
120, 844-851 (2013).
41.   J. Lei, S. Balasubramanian, N. S. Abdelfattah, M. Nittala, S. R. Sadda, Proposal of
a simple optical coherence tomography-based scoring system for progression of age
related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 255, 1551-1558
(2017).
42.   U. Nicolai, C. Eckardt, The occurrence of macrophages in the retina and periretinal
tissues in ocular diseases. *Ger J Ophthalmol* 2, 195-201 (1993).
43.   V. L. Bonilha, B. A. Bell, J. Hu, C. Milliner, G. J. Pauer, S. A. Hagstrom, R. A.
Radu, J. G. Hollyfield, Geographic atrophy: confocal scanning laser ophthalmoscopy,
histology, and inflammation in the region of expanding lesions. *Invest Ophthalmol Vis Sci*
61, 15 (2020).
44.   J. A. Matsubara, Y. Tian, J. Z. Cui, M. R. Zeglinski, S. Hiroyasu, C. T. Turner, D. J.
Granville, Retinal distribution and extracellular activity of granzyme B: a serine protease
that degrades retinal pigment epithelial tight junctions and extracellular matrix proteins.
Front Immunol 11, 574 (2020).
45.   K. C. Chen, J. J. Jung, C. A. Curcio, C. Balaratnasingam, R. Gallego-Pinazo, R.
Dolz-Marco, K. B. Freund, L. A. Yannuzzi, Intraretinal hyperreflective foci in acquired
vitelliform lesions of the macula: clinical and histologic study. *Am J Ophthalmol* 164, 89-
98 (2016).
46.   S. Cherepanoff, P. G. McMenamin, M. C. Gillies, E. Kettle, S. H. Sarks, Bruch's
membrane and choroidal macrophages in early and advanced age-related macular
degeneration. *Br J Ophthalmol* 94, 918-925 (2010).
47.   D. S. McLeod, I. Bhutto, M. M. Edwards, R. E. Silver, J. M. Seddon, G. A. Lutty,
Distribution and quantification of choroidal macrophages in human eyes with age-related
macular degeneration. *Invest Ophthalmol Vis Sci* 57, 5843-5855 (2016).
48.   S. G. Elner, V. M. Elner, J. C. Nielsen, E. Torczynski, R. Yu, W. A. Franklin, CD68
antigen expression by human retinal pigment epithelial cells. *Exp Eye Res* 55, 21-28.
(1992).
49.   O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, G. Tubingen Bevacizumab
Study, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, G. B.
Scharioth, S. Grisanti, Effect of bevacizumab on inflammation and proliferation in human
choroidal neovascularization. *Arch Ophthalmol* 126, 782-790 (2008).
50.   C. M. Sheridan, S. Pate, P. Hiscott, D. Wong, D. M. Pattwell, D. Kent, Expression
of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular
membranes. *Graefes Arch Clin Exp Ophthalmol* 247, 1361-1367 (2009).
51.   S. M. Ghazi-Nouri, A. Assi, G. A. Limb, R. A. Scott, K. von Bussmann, I.
Humphrey, P. J. Luthert, D. G. Charteris, Laser photocoagulation alters the pattern of
staining for neurotrophin-4, GFAP, and CD68 in human retina. *Br J Ophthalmol* 87, 488-
492 (2003).
52.   M. Simsek, S. Ozates, B. Gulpamuk, B. Buyukeren, M. Y. Teke, Dedifferentiation
of retinal pigment epithelium in a patient with chronic retinal detachment. *Ophthalmic*
Surg Lasers Imaging Retina 49, 716-720 (2018).
53.   N. Josifovska, X. Lumi, M. Szatmari-Toth, E. Kristof, G. Russell, R. Nagymihaly, N.
Anisimova, B. Malyugin, M. Kolko, D. Ivastinovic, G. Petrovski, Clinical and molecular
markers in retinal detachment-From hyperreflective points to stem cells and
inflammation. *PLoS One* 14, e0217548 (2019).

54.   J. P. Sarks, S. H. Sarks, M. C. Killingsworth, Evolution of geographic atrophy of the
retinal pigment epithelium. *Eye* 2, 552-577 (1988).
55.   K. Gocho, V. Sarda, S. Falah, J. A. Sahel, M. Benchaboune, M. Ullern, M. Paques,
Adaptive optics imaging of geographic atrophy. *Invest Ophthalmol Vis Sci* 54, 3673-3680
(2013).
56.   P. L. Penfold, M. C. Killingsworth, S. H. Sarks, Senile macular degeneration: the
involvement of immunocompetent cells. *Graefes Arch Clin Exp Ophthalmol* 223, 69-76.
(1985).
57.   F. Sennlaub, C. Auvynet, B. Calippe, S. Lavalette, L. Poupel, S. J. Hu, E.
Dominguez, S. Camelo, O. Levy, E. Guyon, N. Saederup, I. F. Charo, N. V. Rooijen, E.
Nandrot, J. L. Bourges, F. Behar-Cohen, J. A. Sahel, X. Guillonneau, W. Raoul, C.
Combadiere, CCR2(+) monocytes infiltrate atrophic lesions in age-related macular
disease and mediate photoreceptor degeneration in experimental subretinal
inflammation in Cx3cr1 deficient mice. *EMBO Mol Med* 5, 1775-1793 (2013).
58.   S. L. Schlereth, S. Kremers, F. Schrodl, C. Cursiefen, L. M. Heindl,
Characterization of antigen-presenting macrophages and dendritic cells in the healthy
human sclera. *Invest Ophthalmol Vis Sci* 57, 4878-4885 (2016).
59.   M. F. Shirazi, E. Brunner, M. Laslandes, A. Pollreisz, C. K. Hitzenberger, M.
Pircher, Visualizing human photoreceptor and retinal pigment epithelium cell mosaics in
a single volume scan over an extended field of view with adaptive optics optical
coherence tomography. *Biomed. Opt. Express* 11, 4520-4535 (2020).
60.   B. Lee, S. Chen, E. M. Moult, Y. Yu, A. Y. Alibhai, N. Mehta, C. R. Baumal, N. K.
Waheed, J. G. Fujimoto, High-speed, ultrahigh-resolution spectral-domain OCT with
extended imaging range using reference arm length matching. *Translational Vision
Science & Technology* 9, 12-12 (2020).
61.   Z. Wu, C. D. Luu, L. A. B. Hodgson, E. Caruso, N. Tindill, K. Z. Aung, M. B.
McGuinness, G. Makeyeva, F. K. Chen, U. Chakravarthy, J. J. Arnold, W. J. Heriot, S. R.
Durkin, R. H. Guymer, Prospective longitudinal evaluation of nascent geographic atrophy
in age-related macular degeneration. *Ophthalmol Retina*, (2019).
62.   R. Dolz-Marco, K. M. Litts, A. C. S. Tan, K. B. Freund, C. A. Curcio, The evolution
of outer retinal tubulation, a neurodegeneration and gliosis prominent in macular
diseases. *Ophthalmology* 124, 1353-1367 (2017).
63.   M. M. Edwards, D. S. McLeod, I. A. Bhutto, R. Grebe, M. Duffy, G. A. Lutty,
Subretinal glial membranes in eyes with geographic atrophy. *Invest Ophthalmol Vis Sci*
58, 1352-1367 (2017).
64.   L. Chen, J. D. Messinger, D. Ferrara, K. B. Freund, C. A. Curcio, Stages of drusen-
associated atrophy in age-related macular degeneration visible via histologically
validated fundus autofluorescence. *Ophthalmology Retina* 11/30/20 online, (2020).
65.   B. Lujan, A. Roorda, R. W. Knighton, J. Carroll, Revealing Henle's fiber layer using
spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 52, 1486–
1492 (2011).
66.   P. F. Stetson, Z. Yehoshua, C. A. Garcia Filho, R. Portella Nunes, G. Gregori, P. J.
Rosenfeld, OCT minimum intensity as a predictor of geographic atrophy enlargement.
Invest Ophthalmol Vis Sci 55, 792-800 (2014).
67.   A. C. Tan, M. Pilgrim, S. Fearn, S. Bertazzo, E. Tsolaki, A. Morrell, M. Li, J. D.
Messinger, R. Dolz-Marco, M. G. Nittala, J. Lei, S. R. Sadda, I. Lengyel, K. B. Freund, C.
A. Curcio, Calcified nodules in retinal drusen are associated with disease progression
with age-related macular degeneration. *Sci Transl Med* 10, 466-477 (2018).

68. D. Pauleikhoff, C. A. Harper, J. Marshall, A. C. Bird, Aging changes in Bruch's
membrane: a histochemical and morphological study. *Ophthalmology* 97, 171-178
(1990).
69. C. A. Curcio, C. L. Millican, T. Bailey, H. S. Kruth, Accumulation of cholesterol with
age in human Bruch's membrane. *Invest. Ophthalmol. Vis. Sci.* 42, 265-274 (2001).
70. R. F. Mullins, M. N. Johnson, E. A. Faidley, J. M. Skeie, J. Huang, Choriocapillaris
vascular dropout related to density of drusen in human eyes with early age-related
macular degeneration. *Investigative ophthalmology & visual science* 52, 1606-1612
(2011).
71. L. Chen, J. D. Messinger, K. R. Sloan, T. A. Swain, Y. Sugiura, L. A. Yannuzzi, C.
A. Curcio, K. B. Freund, Non-exudative neovascularization supporting outer retina in
age-related macular degeneration, a clinicopathologic correlation. *Ophthalmology* 127,
931-947 (2020).
72. K. G. Chen, J. A. Alvarez, M. Yazdanie, C. Papudesu, W. T. Wong, H. Wiley, E. Y.
Chew, F. L. Ferris, 3rd, C. A. Cukras, Longitudinal study of dark adaptation as a
functional outcome measure for age-related macular degeneration. *Ophthalmology* 126,
856-865 (2019).
73. T. M. Redmond, S. Yu, E. Lee, D. Bok, D. Hamasaki, N. Chen, P. Goletz, J.-X. Ma,
R. K. Crouch, K. Pfeifer, *Rpe65* is necessary for production of 11-*cis*-vitamin A in the
retinal visual cycle. *Nature Genetics* 20, 344-351 (1998).
74. C. L. Nordgaard, K. M. Berg, R. J. Kapphahn, C. Reilly, X. Feng, T. W. Olsen, D. A.
Ferrington, Proteomics of the retinal pigment epithelium reveals altered protein
expression at progressive stages of age-related macular degeneration. *Invest
Ophthalmol Vis Sci* 47, 815-822 (2006).
75. C. Guidry, N. E. Medeiros, C. A. Curcio, Phenotypic variation of retinal pigment
epithelium in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 43, 267-273.
(2002).
76. S. Ghosh, P. Shang, H. Terasaki, N. Stepicheva, S. Hose, M. Yazdankhah, J.
Weiss, T. Sakamoto, I. A. Bhutto, S. Xia, J. S. Zigler, Jr., R. Kannan, J. Qian, J. T.
Handa, D. Sinha, A role for betaA3/A1-crystallin in Type 2 EMT of RPE cells occurring in
dry age-related macular degeneration. *Invest Ophthalmol Vis Sci* 59, AMD104-AMD113
(2018).
77. M. Zhou, J. S. Geathers, S. L. Grillo, S. R. Weber, W. Wang, Y. Zhao, J. M.
Sundstrom, Role of epithelial-mesenchymal transition in retinal pigment epithelium
dysfunction. *Front Cell Dev Biol* 8, 501 (2020).
78. I. A. Bhutto, D. S. McLeod, C. Merges, T. Hasegawa, G. A. Lutty, Localisation of
SDF-1 and its receptor CXCR4 in retina and choroid of aged human eyes and in eyes
with age related macular degeneration. *Br J Ophthalmol* 90, 906-910 (2006).
79. H. Kaneko, S. Dridi, V. Tarallo, B. D. Gelfand, B. J. Fowler, W. G. Cho, M. E.
Kleinman, S. L. Ponicsan, W. W. Hauswirth, V. A. Chiodo, K. Kariko, J. W. Yoo, D. K.
Lee, M. Hadziahmetovic, Y. Song, S. Misra, G. Chaudhuri, F. W. Buaas, R. E. Braun, D.
R. Hinton, Q. Zhang, H. E. Grossniklaus, J. M. Provis, M. C. Madigan, A. H. Milam, N. L.
Justice, R. J. Albuquerque, A. D. Blandford, S. Bogdanovich, Y. Hirano, J. Witta, E.
Fuchs, D. R. Littman, B. K. Ambati, C. M. Rudin, M. M. Chong, P. Provost, J. F. Kugel, J.
A. Goodrich, J. L. Dunaief, J. Z. Baffi, J. Ambati, DICER1 deficit induces *Alu* RNA toxicity
in age-related macular degeneration. *Nature* 471, 325-330 (2011).

80.   M. R. Terluk, R. J. Kapphahn, L. M. Soukup, H. Gong, C. Gallardo, S. R.
Montezuma, D. A. Ferrington, Investigating mitochondria as a target for treating age-
related macular degeneration. *J Neurosci* 35, 7304-7311 (2015).
81.   S. Notomi, K. Ishihara, N. E. Efstathiou, J. J. Lee, T. Hisatomi, T. Tachibana, E. K.
Konstantinou, T. Ueta, Y. Murakami, D. E. Maidana, Y. Ikeda, S. Kume, H. Terasaki, S.
Sonoda, J. Blanz, L. Young, T. Sakamoto, K. H. Sonoda, P. Saftig, T. Ishibashi, J. W.
Miller, G. Kroemer, D. G. Vavvas, Genetic LAMP2 deficiency accelerates the age-
associated formation of basal laminar deposits in the retina. *Proc Natl Acad Sci U S A*
116, 23724-23734 (2019).
82.   J. A. Gambril, K. R. Sloan, T. A. Swain, C. Huisingh, A. V. Zarubina, J. D.
Messinger, T. Ach, C. A. Curcio, Quantifying retinal pigment epithelium dysmorphia and
loss of histologic autofluorescence in age-related macular degeneration. *Invest*
Ophthalmol Vis Sci 60, 2481-2493 (2019).
83.   G. Staurenghi, S. Sadda, U. Chakravarthy, R. F. Spaide, Proposed lexicon for
anatomic landmarks in normal posterior segment spectral-domain optical coherence
tomography: The IN*OCT Consensus. *Ophthalmology* 121, 1572-1578 (2014).
84.   A. A. Sura, L. Chen, J. D. Messinger, T. A. Swain, G. McGwin Jr, K. B. Freund, C.
A. Curcio, Measuring the contributions of basal laminar deposit and Bruch's membrane
in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 61, 19 (2020).
85.   A. C. S. Tan, K. B. Freund, C. Balaratnasingam, D. Simhaee, L. A. Yannuzzi,
Imaging of pigment epithelial detachments with optical coherence tomography
angiography. *Retina* 38, 1759-1769 (2018).
86.   F. A. Jakobiec, P. C. Barrantes, Y. Yonekawa, E. M. Lad, A. D. Proia, Subretinal
mononuclear cells in Coats' disease studied with RPE65 and CD163: evidence for
histiocytoid pigment epithelial cells. *American Journal of Ophthalmology* 222, 388-396
(2020).
87.   A. Bringmann, S. Syrbe, K. Gorner, J. Kacza, M. Francke, P. Wiedemann, A.
Reichenbach, The primate fovea: Structure, function and development. *Prog Retin Eye*
Res 66, 49-84 (2018).
88.   J. Monés, M. Biarnes, F. Trindade, Hyporeflective wedge-shaped band in
geographic atrophy secondary to age-related macular degeneration: an underreported
finding. *Ophthalmology* 119, 1412-1419 (2012).
89.   C. Cukras, E. Agron, M. L. Klein, F. L. Ferris, 3rd, E. Y. Chew, G. Gensler, W. T.
Wong, Natural history of drusenoid pigment epithelial detachment in age-related macular
degeneration: Age-Related Eye Disease Study Report No. 28. *Ophthalmology* 117, 489-
499 (2010).
90.   J. J. Arnold, J. P. Sarks, M. C. Killingsworth, E. K. Kettle, S. H. Sarks, Adult
vitelliform macular degeneration: a clinicopathological study. *Eye* 17, 717-726. (2003).
963